Is ACH or DCGO more profitable?

Accendra Health has a net margin of -39.84% compared to DocGo's net margin of -62.23%. Accendra Health's return on equity of -13.18% beat DocGo's return on equity. Company Net Margins Return on Equity Return on Assets Accendra Health -39.84% -13.18% 1.65% DocGo -62.23% -44.09% -29.14%

Does the media refer more to ACH or DCGO?

In the previous week, Accendra Health had 1 more articles in the media than DocGo. MarketBeat recorded 3 mentions for Accendra Health and 2 mentions for DocGo. DocGo's average media sentiment score of 0.50 beat Accendra Health's score of 0.08 indicating that DocGo is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Accendra Health 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral DocGo 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, DCGO or BDSX?

Biodesix has lower revenue, but higher earnings than DocGo. Biodesix is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DocGo $322.20M 0.19 -$182.40M -$1.91 N/A Biodesix $88.50M 2.67 -$35.26M -$4.06 N/A

Is DCGO or BDSX more profitable?

Biodesix has a net margin of -33.26% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets DocGo -62.23% -44.09% -29.14% Biodesix -33.26% -2,101.40% -35.65%

Does the media prefer DCGO or BDSX?

In the previous week, Biodesix had 7 more articles in the media than DocGo. MarketBeat recorded 9 mentions for Biodesix and 2 mentions for DocGo. Biodesix's average media sentiment score of 0.52 beat DocGo's score of 0.50 indicating that Biodesix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DocGo 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biodesix 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has stronger valuation and earnings, DCGO or INFU?

InfuSystem has lower revenue, but higher earnings than DocGo. DocGo is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DocGo $322.20M 0.19 -$182.40M -$1.91 N/A InfuSystem $143.34M 1.71 $870K $0.41 29.63

Is DCGO or INFU more profitable?

InfuSystem has a net margin of 1.12% compared to DocGo's net margin of -62.23%. InfuSystem's return on equity of 2.78% beat DocGo's return on equity. Company Net Margins Return on Equity Return on Assets DocGo -62.23% -44.09% -29.14% InfuSystem 1.12% 2.78% 1.41%

Does the media refer more to DCGO or INFU?

In the previous week, InfuSystem had 4 more articles in the media than DocGo. MarketBeat recorded 6 mentions for InfuSystem and 2 mentions for DocGo. InfuSystem's average media sentiment score of 0.77 beat DocGo's score of 0.50 indicating that InfuSystem is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DocGo 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InfuSystem 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, LFMD or DCGO?

LifeMD has higher earnings, but lower revenue than DocGo. DocGo is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LifeMD $194.05M 0.92 $14.35M $0.05 73.60 DocGo $322.20M 0.19 -$182.40M -$1.91 N/A

Is LFMD or DCGO more profitable?

LifeMD has a net margin of 2.37% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets LifeMD 2.37% -150.88% -22.59% DocGo -62.23% -44.09% -29.14%

Does the media prefer LFMD or DCGO?

In the previous week, LifeMD had 7 more articles in the media than DocGo. MarketBeat recorded 9 mentions for LifeMD and 2 mentions for DocGo. DocGo's average media sentiment score of 0.50 beat LifeMD's score of -0.24 indicating that DocGo is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LifeMD 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral DocGo 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, JYNT or DCGO?

Joint has higher earnings, but lower revenue than DocGo. DocGo is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Joint $54.90M 2.16 $2.91M $0.23 36.22 DocGo $322.20M 0.19 -$182.40M -$1.91 N/A

Is JYNT or DCGO more profitable?

Joint has a net margin of 5.72% compared to DocGo's net margin of -62.23%. Joint's return on equity of 7.00% beat DocGo's return on equity. Company Net Margins Return on Equity Return on Assets Joint 5.72% 7.00% 2.05% DocGo -62.23% -44.09% -29.14%

Does the media refer more to JYNT or DCGO?

In the previous week, Joint and Joint both had 2 articles in the media. DocGo's average media sentiment score of 0.50 beat Joint's score of 0.00 indicating that DocGo is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Joint 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral DocGo 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

DocGo (DCGO) Competitors

$0.63 -0.02 (-3.76%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$0.64 +0.01 (+1.94%)

As of 04:27 AM Eastern

Compare

DCGO vs. ACH, BDSX, INFU, LFMD, and JYNT

Should you buy DocGo stock or one of its competitors? MarketBeat compares DocGo with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with DocGo include Accendra Health (ACH), Biodesix (BDSX), InfuSystem (INFU), LifeMD (LFMD), and Joint (JYNT). These companies are all part of the "healthcare services" industry.

How does DocGo compare to Accendra Health?

Accendra Health (NYSE:ACH) and DocGo (NASDAQ:DCGO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

In the previous week, Accendra Health had 1 more articles in the media than DocGo. MarketBeat recorded 3 mentions for Accendra Health and 2 mentions for DocGo. DocGo's average media sentiment score of 0.50 beat Accendra Health's score of 0.08 indicating that DocGo is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Accendra Health	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
DocGo	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DocGo has lower revenue, but higher earnings than Accendra Health. DocGo is trading at a lower price-to-earnings ratio than Accendra Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Accendra Health	$2.73B	0.08	-$1.10B	-$14.05	N/A
DocGo	$322.20M	0.19	-$182.40M	-$1.91	N/A

Accendra Health has a beta of 1.58, indicating that its stock price is 58% more volatile than the broader market. Comparatively, DocGo has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market.

Accendra Health presently has a consensus target price of $5.00, indicating a potential upside of 68.35%. DocGo has a consensus target price of $2.38, indicating a potential upside of 278.31%. Given DocGo's stronger consensus rating and higher probable upside, analysts clearly believe DocGo is more favorable than Accendra Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Accendra Health	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Accendra Health has a net margin of -39.84% compared to DocGo's net margin of -62.23%. Accendra Health's return on equity of -13.18% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Accendra Health	-39.84%	-13.18%	1.65%
DocGo	-62.23%	-44.09%	-29.14%

56.4% of DocGo shares are owned by institutional investors. 2.3% of Accendra Health shares are owned by company insiders. Comparatively, 5.1% of DocGo shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

DocGo beats Accendra Health on 9 of the 16 factors compared between the two stocks.

How does DocGo compare to Biodesix?

DocGo (NASDAQ:DCGO) and Biodesix (NASDAQ:BDSX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

Biodesix has a net margin of -33.26% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-62.23%	-44.09%	-29.14%
Biodesix	-33.26%	-2,101.40%	-35.65%

Biodesix has lower revenue, but higher earnings than DocGo. Biodesix is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20M	0.19	-$182.40M	-$1.91	N/A
Biodesix	$88.50M	2.67	-$35.26M	-$4.06	N/A

DocGo currently has a consensus target price of $2.38, indicating a potential upside of 278.31%. Biodesix has a consensus target price of $28.33, indicating a potential upside of 24.38%. Given DocGo's higher probable upside, analysts plainly believe DocGo is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Biodesix had 7 more articles in the media than DocGo. MarketBeat recorded 9 mentions for Biodesix and 2 mentions for DocGo. Biodesix's average media sentiment score of 0.52 beat DocGo's score of 0.50 indicating that Biodesix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DocGo	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biodesix	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

DocGo has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market. Comparatively, Biodesix has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market.

56.4% of DocGo shares are owned by institutional investors. Comparatively, 21.0% of Biodesix shares are owned by institutional investors. 5.1% of DocGo shares are owned by company insiders. Comparatively, 23.2% of Biodesix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

DocGo and Biodesix tied by winning 8 of the 16 factors compared between the two stocks.

How does DocGo compare to InfuSystem?

DocGo (NASDAQ:DCGO) and InfuSystem (NYSE:INFU) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

DocGo has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market. Comparatively, InfuSystem has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market.

DocGo presently has a consensus target price of $2.38, indicating a potential upside of 278.31%. InfuSystem has a consensus target price of $16.67, indicating a potential upside of 37.17%. Given DocGo's higher probable upside, research analysts clearly believe DocGo is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

InfuSystem has lower revenue, but higher earnings than DocGo. DocGo is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20M	0.19	-$182.40M	-$1.91	N/A
InfuSystem	$143.34M	1.71	$870K	$0.41	29.63

InfuSystem has a net margin of 1.12% compared to DocGo's net margin of -62.23%. InfuSystem's return on equity of 2.78% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-62.23%	-44.09%	-29.14%
InfuSystem	1.12%	2.78%	1.41%

56.4% of DocGo shares are held by institutional investors. Comparatively, 71.1% of InfuSystem shares are held by institutional investors. 5.1% of DocGo shares are held by company insiders. Comparatively, 10.8% of InfuSystem shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, InfuSystem had 4 more articles in the media than DocGo. MarketBeat recorded 6 mentions for InfuSystem and 2 mentions for DocGo. InfuSystem's average media sentiment score of 0.77 beat DocGo's score of 0.50 indicating that InfuSystem is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DocGo	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InfuSystem	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

InfuSystem beats DocGo on 13 of the 15 factors compared between the two stocks.

How does DocGo compare to LifeMD?

LifeMD (NASDAQ:LFMD) and DocGo (NASDAQ:DCGO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

LifeMD presently has a consensus price target of $9.14, indicating a potential upside of 148.45%. DocGo has a consensus price target of $2.38, indicating a potential upside of 278.31%. Given DocGo's higher probable upside, analysts plainly believe DocGo is more favorable than LifeMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeMD	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

LifeMD has a net margin of 2.37% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeMD	2.37%	-150.88%	-22.59%
DocGo	-62.23%	-44.09%	-29.14%

In the previous week, LifeMD had 7 more articles in the media than DocGo. MarketBeat recorded 9 mentions for LifeMD and 2 mentions for DocGo. DocGo's average media sentiment score of 0.50 beat LifeMD's score of -0.24 indicating that DocGo is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LifeMD	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
DocGo	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LifeMD has higher earnings, but lower revenue than DocGo. DocGo is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeMD	$194.05M	0.92	$14.35M	$0.05	73.60
DocGo	$322.20M	0.19	-$182.40M	-$1.91	N/A

LifeMD has a beta of 2.02, indicating that its stock price is 102% more volatile than the broader market. Comparatively, DocGo has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market.

35.5% of LifeMD shares are owned by institutional investors. Comparatively, 56.4% of DocGo shares are owned by institutional investors. 17.2% of LifeMD shares are owned by company insiders. Comparatively, 5.1% of DocGo shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

LifeMD beats DocGo on 11 of the 16 factors compared between the two stocks.

How does DocGo compare to Joint?

Joint (NASDAQ:JYNT) and DocGo (NASDAQ:DCGO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Joint currently has a consensus price target of $18.00, suggesting a potential upside of 116.09%. DocGo has a consensus price target of $2.38, suggesting a potential upside of 278.31%. Given DocGo's stronger consensus rating and higher probable upside, analysts plainly believe DocGo is more favorable than Joint.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Joint	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Joint has a net margin of 5.72% compared to DocGo's net margin of -62.23%. Joint's return on equity of 7.00% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Joint	5.72%	7.00%	2.05%
DocGo	-62.23%	-44.09%	-29.14%

Joint has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market. Comparatively, DocGo has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market.

In the previous week, Joint and Joint both had 2 articles in the media. DocGo's average media sentiment score of 0.50 beat Joint's score of 0.00 indicating that DocGo is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Joint	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
DocGo	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

76.9% of Joint shares are held by institutional investors. Comparatively, 56.4% of DocGo shares are held by institutional investors. 30.2% of Joint shares are held by company insiders. Comparatively, 5.1% of DocGo shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Joint has higher earnings, but lower revenue than DocGo. DocGo is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Joint	$54.90M	2.16	$2.91M	$0.23	36.22
DocGo	$322.20M	0.19	-$182.40M	-$1.91	N/A

Summary

Joint beats DocGo on 10 of the 15 factors compared between the two stocks.

Get DocGo News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DCGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DCGO vs. The Competition

Export

Metric	DocGo	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$64.42M	$9.87B	$6.86B	$12.98B
Dividend Yield	N/A	2.56%	2.60%	9.79%
P/E Ratio	-0.33	26.35	280.40	25.25
Price / Sales	0.19	4.78	558.96	76.96
Price / Cash	11.79	125.06	71.79	50.79
Price / Book	0.49	5.24	12.90	6.09
Net Income	-$182.40M	$312.25M	$3.49B	$347.95M
7 Day Performance	-5.86%	0.83%	2.42%	3.08%
1 Month Performance	6.79%	-1.42%	-2.87%	-3.01%
1 Year Performance	-55.48%	25.32%	75.36%	20.49%

DocGo Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DCGO DocGo	3.4729 of 5 stars	$0.63 -3.8%	$2.38 +278.3%	-55.2%	$64.42M	$322.20M	N/A	3,568
ACH Accendra Health	3.4363 of 5 stars	$3.10 -7.2%	$5.00 +61.3%	N/A	$237.41M	$2.72B	N/A	6,500	News Coverage Upcoming Earnings
BDSX Biodesix	3.3588 of 5 stars	$21.20 -0.6%	$28.33 +33.6%	+169.3%	$219.55M	$96.10M	N/A	220	News Coverage Earnings Report
INFU InfuSystem	4.7656 of 5 stars	$9.14 -0.5%	$15.00 +64.1%	+100.2%	$184.46M	$142.40M	152.36	410	News Coverage Analyst Forecast Gap Down
LFMD LifeMD	2.7591 of 5 stars	$3.50 -3.8%	$9.14 +161.2%	-68.9%	$169.27M	$193.33M	70.01	230	Trending News Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DCGO) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DocGo (DCGO) Competitors

DCGO vs. ACH, BDSX, INFU, LFMD, and JYNT

How does DocGo compare to Accendra Health?

Summary

How does DocGo compare to Biodesix?

Summary

How does DocGo compare to InfuSystem?

Summary

How does DocGo compare to LifeMD?

Summary

How does DocGo compare to Joint?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCGO vs. The Competition

DocGo Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DocGo (DCGO) Competitors

DCGO vs. ACH, BDSX, INFU, LFMD, and JYNT

How does DocGo compare to Accendra Health?

Does the media refer more to ACH or DCGO?

Which has higher earnings & valuation, ACH or DCGO?

Which has more risk and volatility, ACH or DCGO?

Do analysts recommend ACH or DCGO?

Is ACH or DCGO more profitable?

Do insiders & institutionals have more ownership in ACH or DCGO?

Summary

How does DocGo compare to Biodesix?

Is DCGO or BDSX more profitable?

Which has stronger earnings & valuation, DCGO or BDSX?

Do analysts prefer DCGO or BDSX?

Does the media prefer DCGO or BDSX?

Which has more volatility & risk, DCGO or BDSX?

Do institutionals and insiders believe in DCGO or BDSX?

Summary

How does DocGo compare to InfuSystem?

Which has more risk & volatility, DCGO or INFU?

Do analysts prefer DCGO or INFU?

Which has stronger valuation and earnings, DCGO or INFU?

Is DCGO or INFU more profitable?

Do insiders & institutionals have more ownership in DCGO or INFU?

Does the media refer more to DCGO or INFU?

Summary

How does DocGo compare to LifeMD?

Do analysts recommend LFMD or DCGO?

Is LFMD or DCGO more profitable?

Does the media prefer LFMD or DCGO?

Which has stronger valuation & earnings, LFMD or DCGO?

Which has more risk and volatility, LFMD or DCGO?

Do insiders & institutionals have more ownership in LFMD or DCGO?

Summary

How does DocGo compare to Joint?

Do analysts rate JYNT or DCGO?

Is JYNT or DCGO more profitable?

Which has more risk and volatility, JYNT or DCGO?

Does the media refer more to JYNT or DCGO?

Do institutionals & insiders hold more shares of JYNT or DCGO?

Which has preferable valuation & earnings, JYNT or DCGO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCGO vs. The Competition

DocGo Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools